Videos

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.

Britny Brown, PharmD, BCOP, discusses the importance of the NCCN guidelines in the treatment of metastatic breast cancer (mBC) and explains how the NCCN recommendations for CDK4/6 inhibitors differ for first-line patients.

Heather Moore, BCOP, CPP, PharmD, discusses patient adherence to CDK4/6 inhibitors in clinical practice, emphasizing the importance of educating patients on drug efficacy and potential toxicities, monitoring for adverse events, and following up with patients to ensure better adherence.

Medical professionals explore social determinants of health, including access to and quality of health care, information sources, community context, and built environment, while also examining the influence of race, ethnicity, language on these factors.

The panelists define vaccine fatigue and identify its primary causes as confusing messaging and the high number of annual vaccinations suggested, emphasizing that the most effective way to combat this fatigue is by tailoring the vaccine information and recommendations to the individual patient's specific needs.

A clinical pharmacist discusses his work in the mental health space while stressing the importance of advocating for and checking in with one another’s emotional well-being.

Tune into this episode of “Public Health Matters” to hear Dr. Kate Gainer’s journey in state pharmacy association and how advocacy and legislative initiatives can benefit pharmacists.

Sarah Rockwell, PharmD, BCOP, provides an overview of the safety and efficacy data of bispecific antibodies investigated in the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 trials, providing critical insights into the results of each study.

Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.

Focusing on PCSK9 inhibitors, inclisiran, and bempedoic acid, the panel compares treatment efficacy and outlines patient factors that influence treatment decisions.

Turning the focus to non-statin therapies, the panel outlines logistical barriers and discusses the characteristics that guide treatment selection in patients with ASCVD.

Key opinion leaders discuss the characteristics they consider when selecting among the different CDK4/6 inhibitors for individual patients, emphasizing the importance of evaluating the toxicity profiles of medications to choose the most appropriate therapy, as well as considering sequencing biomarkers and social determinants of health.

An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.

Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, highlight the crucial role of pharmacies in providing unbiased patient education. They also emphasize the significance of incorporating treatment protocols into medical health records and utilizing various tools to optimize the success of hepatic encephalopathy treatment.

Ralph J. Riello, PharmD, BCPS, discusses the adverse events associated with hepatic encephalopathy (HE) treatments and the importance of encouraging patients to continue first-line medications despite adverse reactions to prevent HE recurrence.

Jeff Goad, PharmD, MPH, stresses the significance of transparency in fostering vaccine confidence by underscoring the ongoing monitoring of vaccines as a means to increase public trust.

Lauren Angelo, PharmD, MBA addresses major factors contributing to vaccine hesitancy, including lack of healthcare provider recommendation and the vaccine's novelty, and provides guidance on counseling patients who are interested in the vaccine but uncertain about its safety and efficacy.

Scott Soefje discusses new treatment options for prostate cancer and highlights the important role pharmacists can play in coordinating care.

Christie Smith discusses navigating state pharmacy laws and advocating for policy changes to improve patient access and care coordination.

Automation has long been viewed as a tool to help improving staffing and workload, but Swanson said it can help a multitude of other challenges, as well.

The vice president of pharmacy operations at American Oncology Network says that pharmacists can contribute by educating patients and offering resources for support and treatment adherence.

Elizabeth Cherry discusses the need to break down silos between manufacturers and health systems specialty pharmacies through more transparent collaboration to better serve patients.

Joe DePinto discusses innovative payment models like value-based agreements and warranties for cell and gene therapies

Sarah Butler discusses the important role pharmacists play in educating patients on these changes in medication prices.

Fran Gregory discusses the challenges posed by rising drug costs and emphasized that optimizing the use of biosimilars, which are entering the market at much lower prices than their reference products.

KOLs emphasize the crucial role of collaboration between pharmacists and physicians in managing hepatic encephalopathy, stressing the importance of monitoring sedating medications, polypharmacy, and patient response to HE therapy, while making necessary adjustments to optimize care.

Medical experts discuss the challenges of starting treatment for newly diagnosed, cognitively impaired patients, addressing prescription processes, patient education, and the role of cost, care quality, and convenience in promoting successful medication adherence.

Clinical pharmacists discuss how to address key barriers that get in the way of implementing guideline-directed cholesterol treatment.

The panel compares the ACC/AHA cholesterol guidelines with the ESC/EAS guidelines and provides thoughts on how educational initiatives can be improved to increase familiarity and implementation.